The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis
Open accessAbstract
There is currently no effective pharmacological treatment for amyotrophic lateral sclerosis (ALS). Because recent evidence suggests that secondary inflammation and caspase activation may contribute to neurodegeneration in ALS, we tested the effects of minocycline, a second-generation tetracycline with anti-inflammatory properties, in mice expressing a mutant superoxide dismutase (SOD1(G37R)) linked to human ALS. Administration of minocycline into the diet, beginning at late presymptomatic stage (7 or 9 months of age), delayed the onset of motor neuron degeneration, muscle strength decline, and it increased the longevity of SOD1(G37R) mice by approximately 5 weeks for approximately 70% of tested mice. Moreover, less activation of microglia was detected at early symptomatic stage (46 weeks) and at the end stage of disease in the spinal cord of SOD1(G37R) mice treated with minocycline. These results indicate that minocycline, which is clinically well tolerated, may represent a novel and effective drug for treatment of ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Rowland, L. P., & Shneider, N. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442207 · Cited by 1,812
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., & Tsai, L.-H. (1999) · Nature · doi:10.1038/45159 · Cited by 1,545
Wong, P. C., Pardo, C. A., Borchelt, D. R., Lee, M. K., Copeland, N. G., Jenkins, N. A., Sisodia, S. S., Cleveland, D. W., & Price, D. L. (1995) · Neuron · doi:10.1016/0896-6273(95)90259-7 · Cited by 1,445
Aging, energy, and oxidative stress in neurodegenerative diseases
Beal, M. F. (1995) · Annals of Neurology · doi:10.1002/ana.410380304 · Cited by 1,440
Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama, E., Reaume, A. G., Scott, R. W., & Cleveland, D. W. (1998) · Science · doi:10.1126/science.281.5384.1851 · Cited by 1,228
Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K. B., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,051
Yrjänheikki, J., Tikka, T., Keinänen, R., Goldsteins, G., Chan, P. H., & Koistinaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,038
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006
Cited by
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors
Boillée, S., Vande Velde, C., & Cleveland, D. W. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.018 · Cited by 1,429
UNRAVELING THE MECHANISMS INVOLVED IN MOTOR NEURON DEGENERATION IN ALS
Bruijn, L. I., Miller, T. M., & Cleveland, D. W. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.27.070203.144244 · Cited by 1,185
Role of Pro-Inflammatory Cytokines Released from Microglia in Neurodegenerative Diseases
Smith, J. A., Das, A., Ray, S. K., & Banik, N. L. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.10.004 · Cited by 1,165
Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice
Clement, A. M., Nguyen, M. D., Roberts, E. A., Garcia, M. L., Boillée, S., Rule, M., McMahon, A. P., Doucette, W., Siwek, D., Ferrante, R. J., et al. (2003) · Science · doi:10.1126/science.1086071 · Cited by 1,100
Self-citationMinocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Selective Ablation of Proliferating Microglial Cells Exacerbates Ischemic Injury in the Brain
Lalancette-Hébert, M., Gowing, G., Simard, A., Weng, Y. C., & Kriz, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5360-06.2007 · Cited by 874
Self-citationRetrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872
Minocycline selectively inhibits M1 polarization of microglia
Kobayashi, K., Imagama, S., Ohgomori, T., Hirano, K., Uchimura, K., Sakamoto, K., Hirakawa, A., Takeuchi, H., Suzumura, A., Ishiguro, N., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.54 · Cited by 742
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
Mejzini, R., Flynn, L. L., Pitout, I. L., Fletcher, S., Wilton, S. D., & Akkari, P. A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01310 · Cited by 755
Turner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C. J., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Banati, R. B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.012 · Cited by 737
“These findings indicate that cerebral microglial activation can be detected in vivo during the evolution of ALS, and support the previous observations that cerebral pathology is widespread.”
BackgroundInfluentialRole of Axonal Transport in Neurodegenerative Diseases
De Vos, K. J., Grierson, A. J., Ackerley, S., & Miller, C. C. J. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.061307.090711 · Cited by 738
Ledeboer, A., Sloane, E. M., Milligan, E. D., Frank, M. G., Mahony, J. H., Maier, S. F., & Watkins, L. R. (2005) · Pain · doi:10.1016/j.pain.2005.02.009 · Cited by 677
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70270-3 · Cited by 649
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease
Philips, T., & Robberecht, W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70015-1 · Cited by 646
The Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
Design, power, and interpretation of studies in the standard murine model of ALS
Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al‐Nakhala, B. M., Vieira, F. G., et al. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960701856300 · Cited by 504
Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS
TURNER, B., & TALBOT, K. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.001 · Cited by 496
The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis
Van Den Bosch, L., Van Damme, P., Bogaert, E., & Robberecht, W. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.05.002 · Cited by 491
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Minocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
Wicks, P., Vaughan, T. E., Massagli, M. P., & Heywood, J. (2011) · Nature Biotechnology · doi:10.1038/nbt.1837 · Cited by 362
Lost in translation: Treatment trials in the SOD1 mouse and in human ALS
Benatar, M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.015 · Cited by 350
Neuroglia in neurodegeneration
Heneka, M. T., Rodríguez, J. J., & Verkhratsky, A. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.11.004 · Cited by 301
Rodent Models of Amyotrophic Lateral Sclerosis
Philips, T., & Rothstein, J. D. (2015) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0567s69 · Cited by 294
Minocycline as a Neuroprotective Agent
Stirling, D. P., Koochesfahani, K. M., Steeves, J. D., & Tetzlaff, W. (2005) · The Neuroscientist · doi:10.1177/1073858405275175 · Cited by 279
Brettschneider, J., Toledo, J. B., Van Deerlin, V. M., Elman, L., McCluskey, L., Lee, V. M.-Y., & Trojanowski, J. Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039216 · Cited by 268
Ballard, C., Mobley, W., Hardy, J., Williams, G., & Corbett, A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00063-6 · Cited by 264
Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment
Ravina, B. M., Fagan, S. C., Hart, R. G., Hovinga, C. A., Murphy, D. D., Dawson, T. M., & Marler, J. R. (2003) · Neurology · doi:10.1212/01.wnl.0000058760.13152.1a · Cited by 262
Microglia and neuroprotection: From in vitro studies to therapeutic applications
Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 262
Human Neural Stem Cell Grafts Ameliorate Motor Neuron Disease in SOD-1 Transgenic Rats
Xu, L., Yan, J., Chen, D., Welsh, A. M., Hazel, T., Johe, K., Hatfield, G., & Koliatsos, V. E. (2006) · Transplantation · doi:10.1097/01.tp.0000235532.00920.7a · Cited by 258
Nguyen, M. D., D'Aigle, T., Gowing, G., Julien, J.-P., & Rivest, S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4786-03.2004 · Cited by 248
Self-citationSriram, K., Miller, D. B., & O'Callaghan, J. P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03566.x · Cited by 242
Papadeas, S. T., Kraig, S. E., O'Banion, C., Lepore, A. C., & Maragakis, N. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103141108 · Cited by 213
“Minocycline, an antibiotic that inhibits microglial activation (31) and confers neuroprotection in ALS mice (28, 29, 36), was used as a pharmacological tool to reduce the contribution of host microgliosis to SOD1 GRP transplant-induced MN death.”
MethodDeleterious Effects of Minocycline in Animal Models of Parkinson’s Disease and Huntington’s Disease
Diguet, E., Fernagut, P., Wei, X., Du, Y., Rouland, R., Gross, C., Bezard, E., & Tison, F. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03372.x · Cited by 189
Jeong, S. Y., Rathore, K. I., Schulz, K., Ponka, P., Arosio, P., & David, S. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5443-08.2009 · Cited by 174
High MMP-9 activity levels in fragile X syndrome are lowered by minocycline
Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., Durbin‐Johnson, B., Hagerman, R. J., & Tassone, F. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36023 · Cited by 161
“…seems to target molecular factors important for neuroprotection as demonstrated by effective treatment in animalmodels ofAlzheimer disease [Choi et al., 2007], Parkinson disease [Wu et al., 2002], Amyotrophic Lateral Sclerosis (ALS) [Kriz et al., 2002], and Huntington disease [Wang et al., 2003].”
BackgroundClinical Potential of Minocycline for Neurodegenerative Disorders
BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157
Amyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications
Cozzolino, M., Ferri, A., & Teresa Carrì, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1760 · Cited by 156
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146
Brettschneider, J., Libon, D. J., Toledo, J. B., Xie, S. X., McCluskey, L., Elman, L., Geser, F., Lee, V. M.-Y., Grossman, M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0932-x · Cited by 142
Dewil, M., dela Cruz, V. F., Van Den Bosch, L., & Robberecht, W. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.023 · Cited by 133
“We and others (Kriz et al., 2002; Van Den Bosch et al., 2002b; Zhu et al., 2002) previously reported minocycline to expand the life span of mutant SOD1 overexpressing mice, an effect associated with a reduction of p38 MAPK activation.”
BackgroundThe brain’s best friend: microglial neurotoxicity revisited
Hellwig, S., Heinrich, A., & Biber, K. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00071 · Cited by 126
The Potential of Minocycline for Neuroprotection in Human Neurologic Disease
Zemke, D., & Majid, A. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000150867.98887.3e · Cited by 125
“With the G37R mutation, minocycline delayed the degeneration of motor neurons and decrease in muscle strength.(52) There was also an increase in the longevity of treated mice.”
BackgroundUtari, A., Chonchaiya, W., Rivera, S. M., Schneider, A., Hagerman, R. J., Faradz, S. M. H., Ethell, I. M., & Nguyen, D. V. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115.5.433 · Cited by 105
Anti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy
Garwood, C. J., Cooper, J. D., Hanger, D. P., & Noble, W. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00136 · Cited by 106
“A biotinylated anti-rabbit IgG secondary antibody (Vector Laboratories) was used in combination with an avidin–biotin peroxidase complex (Vectastain Elite ABC Kit, Vector Laboratories) for antigen detection.”
BackgroundMethodThe Therapeutic Role of Minocycline in Parkinson’s Disease
Cankaya, S., Cankaya, B., Kilic, U., Kilic, E., & Yulug, B. (2019) · Drugs in Context · doi:10.7573/dic.212553 · Cited by 93
The Neuroinflammatory Response in ALS: The Roles of Microglia and T Cells
Lewis, C.-A., Manning, J., Rossi, F., & Krieger, C. (2012) · Neurology Research International · doi:10.1155/2012/803701 · Cited by 76
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
A pilot open-label trial of minocycline in patients with autism and regressive features
Pardo, C. A., Buckley, A., Thurm, A., Lee, L.-C., Azhagiri, A., Neville, D. M., & Swedo, S. E. (2013) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-5-9 · Cited by 58
Baptiste, D. C., Hartwick, A. T. E., Jollimore, C. A. B., Baldridge, W. H., Seigel, G. M., & Kelly, M. E. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001081 · Cited by 55
Gowing, G., Lalancette-Hébert, M., Audet, J.-N., Dequen, F., & Julien, J.-P. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.021 · Cited by 53
Self-citationChallenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Status of ALS treatment, insights into therapeutic challenges and dilemmas
Khamaysa, M., & Pradat, P.-F. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101601 · Cited by 28
Chauhan, P., Kakkar, A. K., Singh, H., & Gautam, C. S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1838276 · Cited by 12
Metadata
- Authors
- Kriz, J., Nguyen, M. D., & Julien, J.-P.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 10
- Issue
- 3
- Pages
- 268-278
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2021374516
- Cited by
- 411
- References
- 45
- FWCI
- 20.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.